Articles Open Access
Like 0
This item has no PDF Download


The current European guidelines recommend that interferon alfa be given in combination with ribavirin as the treatment of choice for patients with moderate or severe hepatitis C virus (HCV) related disease (1). In the United Kingdom, the National Institute for Clinical Excellence (NICE) has endorsed this therapy (2). Recently, however, two types of pegylated interferon, which differ in their pharmacokinetic and chemical properties, have been produced. The addition of polyethyleneglycol to the standard interferon molecule extends its half life thus allowing a more convenient once-weekly dosing regimen with more favourable pharmacokinetic properties.


Article metrics loading...

Loading full text...

Full text loading...

Comment has been disabled for this content
Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error